Albany, NY -- (SBWIRE) -- 02/20/2019 -- Ewing Sarcoma (EFST) - Market and Epidemiology report

19 Feb. 19

The annual incidence of Ewing Sarcoma is 2.93 children per 1,000,000.

1. Approximately 200-250 children and adolescents in the United States are diagnosed with a tumour in the Ewing family of tumours each year.
2. The annual incidence of Ewing Sarcoma is estimated at 1/312,500 in children under the age of 15.
3. The distribution of Ewing Sarcoma in infants is relatively even across the various sites: head (17.7%), upper extremity (17.7%), lower extremity (11.8%), pelvis (17.7%), chest (14.7%), abdomen (11.8%), and spine (8.8%).
4. Ewing tumours of bone account for 37 per cent of the bone tumours occurring in children. Up to 25 children per year are diagnosed in the UK.

(Albany, US) DelveInsight launched Ewing Sarcoma (EFST) - Market and Epidemiology report
Key topics covered

1. The Ewing Sarcoma report provides an in-depth analysis of the disease overview and comprehensive details about treatment algorithms and treatment guidelines for Ewing Sarcoma in the US, Europe, and Japan.
2. The Ewing Sarcoma provides insights about the historical and current patient pool and forecasted trend for 7 major markets.
3. The Ewing Sarcoma report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs.
4. The Ewing Sarcoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market.

Request for sample pages

"Ewing Sarcoma affects males more often than females. It may affect individuals of any age, but most often occurs in individuals between 10 and 20 years of age."

The main treatments for Ewing Sarcoma are chemotherapy, surgery, and radiation. These treatments are often used in some combination with each other. Both surgery and radiation are effective treatments for removing the primary tumour. A typical treatment plan for Ewing Sarcoma includes systemic therapy that treats the entire body, such as chemotherapy or stem cell transplantation, combined with localized therapy. Localized therapy focuses on treating the tumour itself using surgery, radiation therapy, or both. When more than one treatment is used, it is called combination therapy.

Additionally, no specific targeted therapies currently exist for the treatment of Ewing's Family of Tumors (ESFTs). However, this tumour type is associated with a very specific chromosomal abnormality that leads to the expression of a tumour-specific factor that appears to regulate the expression of a variety of proteins. Current research work is aimed at determining which of these proteins are critical for the malignant behaviour of these tumours, with the hope that once identified, these proteins can be the targets for new therapies.

Ewing Sarcoma Companies covered
1. Tyme
2. Gradalis
3. Eisai
And many others

Ewing Sarcoma Drugs covered
1. SM-88
2. Vigil
3. Eribulin
And many others

Ewing Sarcoma Table of contents

1. Ewing Sarcoma Report Introduction
2. Ewing Sarcoma Market Overview at a Glance
3. Ewing Sarcoma Disease Background and Overview
4. Ewing Sarcoma Epidemiology and Patient Population
5. Ewing Sarcoma Epidemiology by Countries
5.1. United States
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.5. France
5.6. Italy
5.7. Spain
5.8. United Kingdom
5.9. Japan
6. Ewing Sarcoma Current Treatment & Medical practices
7. Ewing Sarcoma Unmet Needs of the Ewing Sarcoma
8. Ewing Sarcoma Marketed Therapies
8.1. Drug A: Company 1
8.2. Drug B: Company 2
9. Ewing Sarcoma Pipeline Therapies– At a glance
10. Ewing Sarcoma Key Cross Competition
11. Ewing Sarcoma Emerging Therapies
11.1. Drug C: Company 3
11.2. Drug D: Company 4
12. Ewing Sarcoma 7MM Market Analysis
13.1. United States
13.2. EU-5
13.2.1. Germany
13.2.2. France
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.3. Japan
14. Ewing Sarcoma Market Drivers
15. Ewing Sarcoma Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight